WANYI SCIENCE(SH:688600) Guoxin Securities·2025-11-14 09:12Investment Rating - The report assigns an "Outperform" rating to the company for the first time, with a reasonable valuation range of 28.85 to 30.40 CNY, indicating a potential premium of 22.9% to 29.5% over the current stock price of 23.48 CNY [6][3]. Core Insights - The company is a leading domestic manufacturer of helium mass spectrometers, focusing on industrial detection and online monitoring instruments, while also expanding into laboratory analysis and medical instruments to create a second growth curve [1][2]. - The industrial detection and online monitoring segments are expected to solidify the company's revenue base, with projected revenues of 4.55 billion CNY and 1.98 billion CNY respectively for 2024 [1]. - The laboratory analysis and medical instruments are emerging as new growth engines, with expected revenues of 0.47 billion CNY for laboratory instruments and ongoing development in medical devices [2]. - The company is poised for growth due to recovering product demand, expansion into downstream applications, and strong government support for domestic alternatives in laboratory and medical instruments [3]. Summary by Sections Company Overview - Founded in 2003, the company has evolved from a regional technology firm to a national-level specialized "little giant" and is listed on the Sci-Tech Innovation Board [13]. - The company operates across four main business segments: industrial detection instruments, online monitoring instruments, laboratory analysis instruments, and medical instruments, forming a synergistic growth model [1]. Financial Performance - The company has experienced significant revenue growth, with a compound annual growth rate (CAGR) of 11.99% from 2020 to 2024, despite facing profit pressures due to high R&D investments [23]. - In 2025, the company is expected to see a substantial improvement in performance, with projected revenues of 8.99 billion CNY and net profits of 660 million CNY, reflecting a year-on-year growth of 358.5% [5][3]. Business Segments - The industrial detection segment is the primary revenue contributor, projected to generate 4.55 billion CNY in 2024, while online monitoring instruments are expected to account for 1.98 billion CNY [1][45]. - The laboratory analysis instruments and medical devices are still in the early stages of revenue contribution, with laboratory instruments expected to generate 0.47 billion CNY in 2024 [2][45]. Growth Drivers - The demand for industrial detection instruments is anticipated to benefit from the expansion of major battery manufacturers and government policies aimed at environmental monitoring [3]. - The company has implemented a stock incentive plan to align employee interests with company performance, which is expected to further drive growth [20][21].